Drugs / FAPI GA-68

Trials 18 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 010 trials
Phase 0 NCT06455761 Apr 2024 → Apr 2025 neoplasm First Affiliated Hospital of Fujian Medical University Unknown No outcome recorded
Phase 0 NCT06455735 Mar 2024 → Dec 2025 neoplasm First Affiliated Hospital of Fujian Medical University Unknown No outcome recorded
Phase 0 NCT05952531 Jul 2023 → Jul 2024 idiopathic inflammatory myopathy The First Affiliated Hospital of Xiamen University Unknown No outcome recorded
Phase 0 NCT05691894 Nov 2022 → Nov 2023 cancer Affiliated Hospital of Jiangnan University Unknown No outcome recorded
Phase 0 NCT05543954 Sep 2022 → Dec 2025 overdue lung neoplasm Peking Union Medical College Hospital Recruiting No outcome recorded
Phase 0 NCT05400967 Jan 2022 → Jan 2025 overdue Peking Union Medical College Hospital Recruiting No outcome recorded
Phase 0 NCT05036759 May 2021 → Aug 2023 atherosclerosis Peking Union Medical College Hospital Unknown No outcome recorded
Phase 0 NCT04514614 Sep 2020 → Jan 2022 arthritic joint disease Peking Union Medical College Hospital Unknown No outcome recorded
Phase 0 NCT04507932 Aug 2020 → Jan 2022 inflammatory bowel disease Peking Union Medical College Hospital Unknown No outcome recorded
Phase 0 NCT04596462 Jun 2020 → Jun 2021 SAPHO syndrome Peking Union Medical College Hospital Unknown No outcome recorded
Phase 11 trial
Phase 1 NCT05121779 Nov 2021 → Dec 2025 overdue pulmonary fibrosis Peking Union Medical College Hospital Recruiting No outcome recorded
Phase 1/23 trials
Phase 1/2 NCT07062523 Jul 2024 → Sep 2025 overdue Sjogren syndrome Peking Union Medical College Hospital Recruiting No outcome recorded
Phase 1/2 NCT05990998 Nov 2022 → Aug 2023 First Affiliated Hospital of Fujian Medical University Completed No outcome recorded
Phase 1/2 NCT05275699 Mar 2022 → Feb 2023 keloid Peking Union Medical College Hospital Completed No outcome recorded
Phase 22 trials
Phase 2 NCT07083011 Nov 2025 → Jul 2027 expected diastolic heart failure Mayo Clinic Recruiting No outcome recorded
Phase 2 NCT04023240 Jul 2023 cancer Stanford University Withdrawn No outcome recorded
Phase not applicable2 trials
NCT05499936 Oct 2021 → Oct 2022 adenoid cystic carcinoma Peking Union Medical College Hospital Unknown No outcome recorded
NCT05034146 Feb 2021 → Dec 2025 overdue cancer Zhongnan Hospital Recruiting No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 0 NCT06740240 Comparator Mar 2024 → Jun 2026 overdue neoplasm First Affiliated Hospital of Fujian Medical University Recruiting No outcome recorded

Evidence & citations 9 cited values

Every value below carries the sentence it was read from. 21 sources stand behind the page.

FieldValueCited text
Known as FAPI GA-68 ChEMBL registry synonym — accepted as the source's own label CHEMBL4650356
Known as 68Ga-FAPI ClinicalTrials.gov intervention name — accepted as the source's own label NCT07062523
18

NCT05990998

NCT07083011

NCT04514614

NCT05952531

NCT06455761

NCT05400967

NCT05275699

NCT05121779

NCT06455735

NCT05543954

NCT04596462

NCT06740240

NCT05034146

NCT05499936

NCT04507932

NCT04023240

NCT05036759

NCT05691894

Known as [68 Ga]Ga-FAPI “Gallium-68-labelled fibroblast activation protein inhibitor ([68 Ga]Ga-FAPI) is a tumour-stromal imaging agent showing complementary value alongside fluorine-18...” PMID 40614035 Jul 2025
Known as Fapi-02 ga-68 ChEMBL registry synonym — accepted as the source's own label CHEMBL4650356
Known as Fapi-2 ga-68 ChEMBL registry synonym — accepted as the source's own label CHEMBL4650356
Action Inhibit “gallium 68-labelled FAP inhibitor (68Ga-FAPI)” NCT05034146
Modality Diagnostic / imaging agent “68Ga-FAPI as the imaging agent for positron emission tomography (PET)/computed tomography (CT)” NCT04023240
Route Intravenous “68Ga-FAPI is administered intravenously (IV)” NCT04023240
Target FAP “68Ga-FAPI that targets fibroblast activation protein (FAP)” NCT04596462